ATTENTION DEFICIT HYPERACTIVITY DISORDER TREATMENT MARKET ANALYSIS

Attention Deficit Hyperactivity Disorder Treatment Market, by Drug Type (Stimulants (Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, Lisdexamfetamine Dimesylate), Non-stimulants (Atomoxetine, Bupropion, Guanfacine, Clonidine)), by Age Group (Pediatric and Adolescent, Adult), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Oct 2022
Code : CMI830
Pages :181
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Major players operating in the global attention deficit hyperactivity disorder treatment market include Amnel Pharmaceuticals LLC., Eli Lilly And Company, Johnson & Johnson Services, Inc., Noven Pharmaceuticals, Inc, RespireRx Pharmaceuticals Inc, Otsuka Pharmaceutical Co., Ltd, Neos Therapeutics, Inc., American Brivision (Holding) Corporation, Novartis AG, Takeda Pharmaceutical Company Limited, GSK plc, Purdue Pharma L.P. ,Cingulate, Adlon Therapeutics L.P., Tris Pharma, Inc.,Neuraxpharm, Supernus Pharmaceuticals,Inc., and Aytu Biopharma, Inc.